Skip to Content
Merck
CN

H2380

6-Hydroxy-DL-DOPA

≥98% (HPLC), powder, APE1 inhibitor

Synonym(s):

2,4,5-Trihydroxy-DL-phenylalanine, 2,5-Dihydroxy-DL-tyrosine

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C9H11NO5
CAS Number:
21373-30-8
Molecular Weight:
213.19
Beilstein:
2860065
MDL number:
MFCD00004272
UNSPSC Code:
12352200
PubChem Substance ID:
24278464
NACRES:
NA.32

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

6-Hydroxy-DL-DOPA, ≥98% (HPLC), powder

Quality Level

200

Assay

≥98% (HPLC)

form

powder

color

off-white

solubility

H2O: 3 mg/mL
1 M HCl: 50 mg/mL (Solutions should be freshly prepared and protected from exposure to light.)

storage temp.

−20°C

SMILES string

NC(Cc1cc(O)c(O)cc1O)C(O)=O

InChI

1S/C9H11NO5/c10-5(9(14)15)1-4-2-7(12)8(13)3-6(4)11/h2-3,5,11-13H,1,10H2,(H,14,15)

InChI key

YLKRUSPZOTYMAT-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Dissolve in oxygen-free boiled water containing 0.1% sodium metabisulfite or other antioxidant. Solutions should be freshly prepared and protected from exposure to light.

Biochem/physiol Actions

6-Hydroxy-DL-DOPA is an inhibitor of APE1 (apurinic/apyrimidinic endonuclease) repair-function activity. APE1 is a nuclease crucial for DNA base excision repair pathway. 6-Hydroxy-DL-DOPA also blocks RAD52 (DNA repair protein) single-stranded DNA binding domain.
Precursor 6-hydroxydopamine.
Precursor of the catecholaminergic neurotoxin, 6-hydroxydopamine; converted to 6-hydroxydopamine by L-aromatic amino acid decarboxylase.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Disclaimer

Hygroscopic; photosensitive

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCN3947
BCCM0465
BCCM5089
BCCL2530
BCCK4047

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Gurushankar Chandramouly et al.
Chemistry & biology, 22(11), 1491-1504 (2015-11-10)
Suppression of RAD52 causes synthetic lethality in BRCA-deficient cells. Yet pharmacological inhibition of RAD52, which binds single-strand DNA (ssDNA) and lacks enzymatic activity, has not been demonstrated. Here, we identify the small molecule 6-hydroxy-DL-dopa (6-OH-dopa) as a major allosteric inhibitor
Mass spectrometric studies of the primary sequence and structure of bovine liver and serum amine oxidase.
G W Adams et al.
Methods in enzymology, 258, 90-114 (1995-01-01)
Adnan Azeem et al.
International journal of pharmaceutics, 422(1-2), 436-444 (2011-11-08)
Ropinirole, a recent introduction in the clinical treatment of Parkinson's disease, suffers with the problems of low oral bioavailability and frequent dosing. An effective transdermal nano-emulsion drug delivery system can however resolve these issues effectively with greater therapeutic benefits and
A J Nappi et al.
Biochimica et biophysica acta, 1201(3), 498-504 (1994-12-15)
The interactions of ascorbic acid (AA) and reduced glutathione (GSH) in the oxidations of the catecholaminergic neurotoxins 6-hydroxydopa (TOPA) and 6-hydroxydopamine (6-OHDA) were investigated by both high performance liquid chromatography with electrochemical detection (HPLC-ED) and spectrometric methods. These comparative studies
Annalisa Pinna et al.
Synapse (New York, N.Y.), 61(8), 606-614 (2007-05-04)
Evidence obtained in rodent and primate models of Parkinson's disease (PD) and preliminary clinical trials, indicates that adenosine A(2A) receptor antagonists might represent a promising nondopaminergic therapeutic tool for the treatment of PD. Those studies demonstrated the ability of adenosine
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service